The potential merger between Cigna Group and Humana Inc., two renowned entities in the healthcare insurance sector, is expected to attract formidable antitrust scrutiny, reminiscent of challenges faced by previous colossal mergers in the industry. This is in line with the recent trend of stringent examination of large corporate agreements by antitrust regulators, indicating that their approval is far from guaranteed.
Nevertheless, an interesting strategy that could potentially alleviate antitrust concerns revolves around Cigna offloading some of Humana’s Medicare business. This tactic could mollify regulators by demonstrating a commitment to preserving competition within the marketplace. But it’s worth noting that this strategy, while potentially beneficial, is speculative at the current stage and would not entirely ensure deal approval.
To expand further, any move involving Humana’s Medicare business could potentially soften the regulatory blow. Humana’s chief strength lies in Medicare Advantage, the privately run version of the U.S. federal health program for seniors. It supports over 4.8 million members, constituting a significant share of the market. If Cigna were to divest some of this business, this could go a long way in assuaging antitrust concerns.
These maneuvers are critical given the current regulatory climate. Antitrust authorities have a recent record of cracking down on mega mergers of health insurers. For instance, in 2016, federal judges axed Aetna’s $37 billion bid for Humana, as well as Anthem’s $54 billion pursuit of Cigna, identifying valid competition concerns.
The developing Cigna-Humana scenario will be an interesting one to monitor for all legal professionals in the corporate sector, particularly those within the healthcare and insurance verticals. This offers a clear example of the challenges lying at the intersection of corporate legal strategy and antitrust law, underlining the imperative for tact, foresight, and strategic dexterity during negotiations and potential mergers.
For more coverage and analysis of this developing story, see the full report here.